Jerald P. Radich

Oncology

1100 Fairview Ave N
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 230 publications

Introduction to the Review Series. Chronic myeloid leukemia in 2026.

Introduction to the Review Series. Chronic myeloid leukemia in 2026.

Journal: Haematologica

Published: July 01, 2026

Chronic Myeloid Leukemia in Low- and Middle-Income Countries. Reply.

Chronic Myeloid Leukemia in Low- and Middle-Income Countries. Reply.

Journal: The New England journal of medicine

Published: June 03, 2026

Portrait of a Pioneer: Fred Appelbaum.

Portrait of a Pioneer: Fred Appelbaum.

Journal: Transplantation and cellular therapy

Published: May 20, 2026

Chronic Myeloid Leukemia in Low- and Middle-Income Countries: Increasing Access to Tyrosine Kinase Inhibitors and Supporting Treatment-Free Remission.

Chronic Myeloid Leukemia in Low- and Middle-Income Countries: Increasing Access to Tyrosine Kinase Inhibitors and Supporting Treatment-Free Remission.

Journal: Clinical lymphoma, myeloma & leukemia

Published: May 18, 2026

Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries.

Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries.

Journal: The New England journal of medicine

Published: March 25, 2026

Multiomic Single-Cell Sequencing Identifies BCR::ABL1 as an Acquired Resistance Mechanism in FLT3+ AML.

Multiomic Single-Cell Sequencing Identifies BCR::ABL1 as an Acquired Resistance Mechanism in FLT3+ AML.

Journal: European journal of haematology

Published: March 25, 2026

Personalized measurable residual disease assays for acute myeloid leukemia guided by whole-genome sequencing.

Personalized measurable residual disease assays for acute myeloid leukemia guided by whole-genome sequencing.

Journal: Haematologica

Published: February 12, 2026

Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia.

Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia.

Journal: medRxiv : the preprint server for health sciences

Published: February 06, 2026

A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®).

A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®).

Journal: Future oncology (London, England)

Published: February 06, 2026

A Framework for Locally Imputing and Predicting Biomarker Trajectories Under Irregular Monitoring: Application to Chronic Myeloid Leukemia.

A Framework for Locally Imputing and Predicting Biomarker Trajectories Under Irregular Monitoring: Application to Chronic Myeloid Leukemia.

Journal: Research square

Published: January 16, 2026

Predictive biomarkers of sustained treatment-free remission in chronic myeloid leukemia: gene expression analyses from the ENESTfreedom and ENESTop studies.

Predictive biomarkers of sustained treatment-free remission in chronic myeloid leukemia: gene expression analyses from the ENESTfreedom and ENESTop studies.

Journal: Haematologica

Published: December 11, 2025

Prognostic impact of age and MDS-associated mutations in NPM1 -mutated AML.

Prognostic impact of age and MDS-associated mutations in NPM1 -mutated AML.

Journal: medRxiv : the preprint server for health sciences

Published: November 24, 2025

Showing 1-12 of 230

Last Updated: 09/26/2026